Merck Healthcare announced a license agreement with Abbisko Therapeutics for pimicotinib, which is currently being evaluated in a Phase 3 study for the treatment of tenosynovial giant cell tumor.
Merck Healthcare today announced a license agreement with Abbisko Therapeutics Co. Ltd, Shanghai, China, for pimicotinib (ABSK021), which is currently being evaluated in a Phase III study for the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a benign…